PPARA and Alzheimer disease: The potential use of GSK-3β as a clinical target in AD has been discussed, including the activation of M1 muscarinic receptor and PKC, the use of anti-inflammatory-ChE bifunctional compounds, PPAR agonists, and some antioxidants, all of which may play a role by regulating the Wnt/β-catenin signaling.